Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Dissemination indices derived from [F]FDG PET/CT, such as Dmax, Dmax, SPREAD, SPREAD, and Dmax are validated prognostic biomarkers in diffuse large B-cell lymphoma. We introduce Dmax, the distance between the outermost voxels of the two most distant lesions on a 2D maximum intensity projection image, which is easy and straightforward to obtain. Our goal is to evaluate Dmax's prognostic value compared to other features for easier clinical application.
Methods: Metabolic tumor volume and dissemination indices were obtained from LIFEx, while Dmax was obtained from Telemis and OsiriX.
Results: Dmax was not significantly higher in deceased than in living patients. However, patients with Dmax values above the derived cutoff showed a shorter survival. By combining MTV and Dmax, we obtained 3 risk groups for OS and PFS.
Discussion: Dmax could advantageously replace other dissemination parameters as a prognostic index in patients with DLBCL.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301333 | PMC |
| http://dx.doi.org/10.3389/fmed.2025.1565525 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multimodal ultrasonographic and clinicopathological model for predicting high-volume lymph node metastasis in cN0 papillary thyroid carcinoma.
Front Endocrinol (Lausanne)
September 2025
Department of Medical Ultrasound, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Background: Given the challenge in preoperative diagnosis of high-volume lymph node metastasis (HVLNM) in clinical practice, we constructed and externally validated a comprehensive predictive model that integrated conventional ultrasound characteristics, contrast-enhanced ultrasound (CEUS) parameters, BRAFmutation, and clinicopathological data for HVLNM in clinically lymph node-negative (cN0) papillary thyroid carcinoma (PTC).
Methods: Totally, 126 clinically lymph node-negative (cN0) PTC patients who underwent subtotal or total thyroidectomy and accompanied with prophylactic cervical lymph node dissection between December 2022 and December 2024 were enrolled in this retrospective study, and an additional 47 cN0 PTC patients included for the external validation cohort. Univariate and multivariate analysis were performed to identify the independent risk factors for HVLNM, and a binary logistic regression equation and relevant nomogram was constructed to predict the risk about HVLNM.
Dosimetric Outcomes of SBRT to Ultra-central Lung Tumors: Lessons from the SUNSET trial.
Int J Radiat Oncol Biol Phys
September 2025
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. Electronic address:
Purpose / Introduction: The BLINDED FOR REVIEW trial investigated the maximum tolerated dose for ultracentral lung tumors treated with stereotactic body radiotherapy (SBRT). Here we report a spatial and dosimetric secondary analysis of the treatment plans and assess relationships between doses to targets, organs-at-risk (OARs) and clinical outcomes.
Material And Methods: Five institutions enrolled patients with ultracentral lung cancer, cT1-3N0M0, and all received 60 Gy in 8 fractions.
Inhibition of Mycobacterium tuberculosis UvrB by small molecules: Potent NER disruption and structural insights into dimer conformation.
Int J Biol Macromol
September 2025
Biochemistry and Structural Biology Division, CSIR-Central Drug Research Institute, Lucknow, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India. Electronic address:
The nucleotide excision repair (NER) pathway in Mycobacterium tuberculosis (Mtb) is important for DNA damage repair and bacterial survival under stress, yet specific inhibitors targeting its components remain scarce. Here, we targeted the UvrB protein, a central component of the Mtb UvrABC NER pathway, and identified novel small molecule inhibitors against its nucleotide binding domain (NBD). Using in silico structure-based screening involving the Maybridge library (~54,000 compounds), Molecular dynamics (MD) simulations, and Biolayer interferometry (BLI), we identified four potent inhibitors: SPB08143, RJC04069, NRB00936, and DP00786 with IC50 values of 9.
View Article and Find Full Text PDFAdvancements in nasopharyngeal carcinoma radiotherapy: Dosimetric evaluation of arc therapy with hippocampal sparing.
Cancer Treat Res Commun
August 2025
Faculty of medicine and Pharmacy Casablanca (FMPC), Hassan II University, Morocco; Mohammed V Military Teaching Hospital, Rabat, Morocco.
Background: Nasopharyngeal carcinoma (NPC) is located near critical structures like the hippocampus, essential for memory and cognitive function. While Volumetric Modulated Arc Therapy (VMAT) has improved dose conformity in NPC treatment, the integration of hippocampal-sparing (HS) approaches remains underexplored. This study evaluates the dosimetric feasibility and effectiveness of hippocampal-sparing VMAT (HS-VMAT) in NPC, focusing on reducing radiation exposure to the hippocampus while maintaining target volume coverage.
View Article and Find Full Text PDFDevelopment of Degraders and 2-pyridinecarboxyaldehyde (2-PCA) as a recruitment Ligand for FBXO22.
bioRxiv
August 2025
Department of Chemical and Systems Biology, ChEM-H and Stanford Cancer Institute, Stanford Medical School, Stanford University, Stanford, CA, 94305, USA.
Targeted protein degradation (TPD) is a promising therapeutic strategy that requires the discovery of small molecules that induce proximity between E3 ubiquitin ligases and proteins of interest. FBXO22 is an E3 ligase that is overexpressed in many cancers and implicated in tumorigenesis. While FBXO22 was previously identified as capable of recognizing ligands bearing a primary amine degron, further investigation and development of recruitment ligands is required to enable its broader utility for TPD.
View Article and Find Full Text PDF